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1. Introduction 
Human post-heparin plasma contains two major 
lipase activities designated lipoprotein lipase (LPL) 
and hepatic lipase (HL) [1-3]. LPL is activated by 
apoC-II [4,5] and aport (/32 glycoprotein I) [6]. Type 
I hyperlipoproteinemia is associated with a deficiency 
in the enzymic activity of LPL [7]. A deficiency in 
apoC-1I also results in type I hyperlipoproteinemia 
[8] and LPL and apoC-I1 have therefore been proposed 
to be of major importance in modulating the catabo- 
lism of triglyceride-rich lipoproteins inman. The func- 
tion, natural substrate and regulation of the enzymic 
activity of ilL have been less well defined. HL activity 
in human post-heparin plasma is decreased in patients 
with liver disease and renal failure [9-1 1]. An inverse 
correlation between HL enzymic activity and the con- 
centration of high density lipoproteins (HDL, 
d= 1.063-1.21 g/ml [12]) as well as HDL2 (d-- 1.063- 
1.125 g/ml) has been reported and it has been suggested 
that HL may play a role in the catabolism of HDL2 
[13]. HL enzymic activity has been reported to be 
inhibited by apolipoproteins C-I, C-II and C-III, and 
increased by high concentrations of NaC1 and serum 
[14]. In initial studies we have also observed that 
human plasma activates HL enzymic activity. It was 
the purpose of this study to further define the com- 
ponent within plasma which is responsible for this 
activation. The results of our investigations indicate 
that under the conditions tudied, apoA-II, a protein 
constituent of human HDL activates HL. 
2. Materials and methods 
2.1. Enzyme source 
Plasma was obtained from normal fasting subjects 
following intravenous injection of sodium heparin 
(75 U/kg body wt, beef lung heparin, Upjohn Co.). 
Blood was collected 15 min after injection, mixed 
with 0.25 M sodium citrate (0.05 ml/ml blood, J. T. 
Baker Chemical Co.) and centrifuged at 2000 rev./ 
rain for 30 rain in a Sorvall RC-3 centrifuge (Dupont 
Instr.) at 4°C. The plasma was aspirated and stored 
at -70°C until used. 
HL was isolated from human post heparin plasma 
by affinity chromatography on heparin-Sepharose 
CL-6B (Pharmacia Fine Chemicals). The heparin affin- 
ity column (Isolab, QS-6E, 0.6 X 1.75 cm) was equili- 
brated with buffer A (5 mM barbital buffer, 0.4 M 
NaC1, pH 7.4) and 2 ml post-heparin plasmi adiluted 
1:2 with buffer A were applied to the column. The 
column was developed with 8 ml buffer A, and hepatic 
lipase eluted with I ml buffer B (5 mM barbital buffer, 
0.7 M NaC1, pH 7.4). The column was washed with 
8 ml buffer B and lipoprotein lipase was eluted with 
1 ml buffer C (5 mM barbital buffer, 1.5 M NaC1, 
pH 7.4). Purified enzymes were stored at -70°C if 
not used immediately. 
2.2. Substrate 
9,10(n)- [3HI glycerol triolate (triolein), 121 Ci/ 
retool, (New England Nuclear) in hexane and unla- 
beled triolein (Applied Science Labs. Inc.) were repuri- 
fled by column chromatography using silicic acid 
(Mallinckrodt, 100 mesh) and Florisil (Fisher, 
60-100 mesh) [15]. Petroleum ether (Burdick 
and Jackson Labs. Inc.) and anhydrous ethyl ether 
(Mallinckrodt) were used for column chromatography. 
Anhydrous emulsions of [3HI triolein in glycerol (J. Y. 
Baker Chemical Co.) were prepared as in [15] using 
lecithin from egg yolk (Sigma) as stabilizer. Assay sub- 
strate [7.2 mM [3H]triolein (5 X 103 dpm/nmol tri- 
olein), 2% bovine serum albmnin (BSA) (Sigma frac- 
tion V), 0.13 M Tris-HC1 (pH 8.6)] were prepared 
daily by dilution of anhydrous emulsions with 0.3 M 
Tris-HC1 (pH 8.6) containing 5% BSA. 
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2.3. Assay systems 
Assays of HL and LPL activity were performed in 
2 mM [all] triolein, 87 mM Tris-HC1, 2% BSA, 75 mM 
NaC1, 50 mM ammonium bicarbonate, 0.25 mM bar- 
bital buffer (final pH 8.6) in 200 tal; 10 tal enzyme 
preparation were assayed each time. The amount of 
protein or volume of plasma with different experiments 
is indicated in the figure legend. The incubations were 
initiated by addition of enzyme. The incubations were 
carried out for 30 rain at 37°C in a shaking waterbath. 
The reaction was terminated and the assay products 
analyzed by the method in [16]. The assay was linear 
during the time course of these experiments and over 
the range of the enzyme concentrations u ed. 
2.4. Purification of apolipoproteins 
ApoA-II and apoC-II were purified as in [17,18]. 
ApoA-II was dissolved in 6 M guanidine, 0.01 M Tris, 
0.1 M NaCI (pH 7.4) and dialyzed against 0.01 M 
ammonium bicarbonate (pH 8.6). Protein was deter- 
mined as in [19]. 
3. Results and discussion 
In these studies we investigated the effect of plasma, 
apoA-II and apoC-lI and HL enzymic activity. The 
addition of normal plasma (20 tal/200 tal assay volume) 
increased HE enzymic activity by 240 + 60%. Isolated 
apoA-lI increased HL activity by 361 -+ 96% under 
these assay conditions. A representative curve of HL 
enzymic activity as a function of increasing concen- 
trations of apoA-II is shown in fig. 1 a. Activation 
occurred at low protein concentrations and reached a
plateau at 20 tag protein/ml; based on M r = 17 380 this 
value corresponds to 1.2 taM apoA-II, In some experi- 
ments at higher concentrations of apoA-II (>100 tag/ 
ml), the degree of activation declined. 
Increasing concentrations of apoC-II in this assay 
system inhibited HL enzymic activity, with >80% 
inhibition observed at 10 ~uM apoC-II (fig. 1 c). Apoc-II 
at 10 tag/ml increased LPL activity >10-fold (fig.ld). 
The activation of LPLby apoC-1I was partially reversed 
by increasing concentrations of apoA-lI (fig.lb). It is 
important o note that all of these effects occur: (i) 
at taM levels; and (ii) in the presence of a 200-fold 
greater concentration of bovine serum albumin. Thus 
the activation of HL by apoA-lI appears to be specific 
and parallels closely the activation of LPL by apoC-II. 
The modulation of LPL enzymic activity by apolipo- 
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Fig.1. Effect of apolipoproteins A-II and C-II on HL and LPL 
enzymic activity. The enzymic activities of HL and LPL as a 
function of the concentration f apoA4I and apoC-II were 
studied: the effect of apoAqI on HL and LPL is given in (a) 
and (b), respectively and the effect of apoC-II on HL and LPL 
is given in panels (d) and (c) respectively. Assay conditions: 
2 mM [3H]triolein, 87 mM Tris-HC1, 2% BSA, 75 mM NaC1, 
50 mM ammonium bicarbonate, 0.25 mM barbital (final 
pH 8.6) in a total volume of 200 ~1. For the experiment shown 
in (b) apoC-II (10/~g/ml) was included in all assays. 
protein C-II has been actively investigated [4,5,20-22] 
and the physiological importance of this regulation is 
apparent from the low LPL activity and hypertriglycer- 
idemia reported in patients with apoC-II deficiency 
[8]. The regulation of HL activity has received much 
less attention [3,14] and there has been, to our knowl- 
edge, no previous report of specific activators of this 
enzyme. It is known, however, that HL enzymic activ- 
ity is enhanced by the addition of serum [14]. We have 
confirmed those findings and in these studies report 
that isolated apolipoprotein A-II activates HL. Under 
the assay conditions employed a 3-fold increase in HL 
activity was observed with the addition of taM quanti- 
ties of apoA-II. The mechanism by which apoA-II 
activates HTGL enzymic activity in vitro remains to 
be determined. A comparison of the effects of apoA-I1 
and apoC-II on HL and LPL enzymic activities uggests 
a similar mode of action for both apolipoproteins with 
regard to the in vitro hydrolysis of triolein emulsions. 
Reports from several laboratories provide evidence 
that HL may play an important role in HDL metabo- 
lism. In the human, HDIa phospholipid and choleste- 
rol concentrations are negatively correlated with 
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plasma HL enzymic activity [ 13]. HDL2 cholesterol 
concentrations are also inversely correlated with HL 
enzymic activity in patients with primary biliary 
cirrhosis (unpublished). In the rat inhibition of HL 
enzymic activity after injection of a specific anti-HL 
antibody resulted in an increase of phospholipids and 
cholesterol in the HDL2 density range (1.005-1.13 g/ 
ml) [12,22] while HDL3 lipid concentrations were 
reduced [12,22]. In addition, it has been reported in 
the rat that HL can hydrolyze HDL2 phospholipids 
and the authors uggested that HL may be involved 
in the in vivo conversion of HDL2 to HDL3 [24]. 
ApoA-II is a major protein constituent of human plasma 
HDL and our results demonstrate hat apoA-II in vitro 
activates HL enzymic activity. Our results are consistent 
with the concept hat apoA-lI increases the rate of 
HDL2 metabolism through modulation of i lL enzymic 
activity. The cofactor function ofapoA-II is analogous 
to the cofactor functions of apoC-ll for LPL in the 
metabolism of triglyceride-rich lipoproteins and apoA-I 
for lecithin cholesterol acyltransferase (LCAT) in the 
esterification of cholesterol (fig.2). Thus the enzymic 
activities of 3 enzymes involved in lipid metabolism 
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Fig.2. Current concepts of the regulation of HDL metabolism. 
Lipoprotein lipase (LPL) and its cofactor, apoC-ll, catalyze 
the hydrolysis of chylomicron and VLDL triglycerides with 
the formation of remnant particles and the net transfer of 
apolipoproteins and lipids to HDL 3 and the conversion of 
HDL 3 to HDL2. Within HDL lecithin cholesterol acyl trans- 
ferase (LCAT) and its cofactor, apoA4, catalyze the esterifi- 
cation of cholesterol to cholesterol esters. Hepatic lipase (HL) 
and its cofactor, apoA-II, catalyze the hydrolysis of lipids 
within HDL 2 with conversion of HDL 2 to HDL3, the uptake 
of lipoprotein constituents bytissues and the net transfer of 
cholesterol ester and phospholipids tochylomicrons, VLDL, 
and LDL by exchange proteins. 
(e.g., LPL, LCAT and HL) are regulated by apolipo- 
proteins (e.g., apoC-II, apoA-I and apoA-II, respec- 
tively). 
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